Science that moves
medicine forward.
Celutron's research programs span the full tissue engineering pipeline, from fundamental biomaterial science to clinical-grade tissue fabrication systems.
Active Research Areas
Hover or select a research competency to view its active clinical validation study, engineering specifications, and custom CAD schematic.
Tissue Engineering
Design and fabrication of functional 3D constructs to restore, maintain, or improve damaged skeletal tissues.
Stem Cell Systems
Harnessing pluripotency, bio-active signaling, and cellular cargo pathways to drive localized tissue renewal.
Regenerative Medicine
Translating cellular therapies and advanced biological membranes from lab bench to in-vivo wound recovery.
Scaffold Development
Engineering porous, tridimensional, biocompatible structural lattices that mimic native extracellular matrices.
Bioprinting Methodologies
Developing extrusion, fluid-flow, and layer-by-layer deposition systems for cell-laden hydrogels.
Material Science
Synthesizing non-toxic, bioresorbable, shear-thinning polymers and nanoparticles from sustainable resources.
Bone Scaffold (Tri-Component)
Nomenclature: Pluronic-Assisted Alginate-Hydroxyapatite Bioink for 3D Bioprinting of Bone Tissue Scaffolds
Scientific Narrative & Purpose
Bones have an incredible natural ability to heal themselves, but when damage is too severe — from major injuries, illness, or bone loss due to age — the body sometimes needs extra help to rebuild what's missing. This project explores an innovative way to give that help: using a specially designed printable material, almost like a biological ink, to build tiny scaffolds that guide bone to grow back naturally. Made from a thoughtful blend of bone-friendly and body-safe ingredients, this bioink is engineered to be soft and flexible enough to print with precision, while still providing the right support and structure for new bone cells to take hold and thrive. Using advanced 3D printing techniques, these scaffolds can be shaped to match a patient's exact needs, offering a personalized foundation for healing rather than a one-size-fits-all solution. Over time, as the body's own bone tissue grows into the scaffold, the printed structure works alongside nature, encouraging real, lasting repair instead of relying on permanent artificial parts. This research aims to bring us closer to a future where bone injuries and defects can be treated with solutions that are safer, more personalized, and more in tune with the body's own healing process — turning cutting-edge printing technology into real, meaningful care for patients.
Research Limitation
Mono-component alginate bioinks show poor extrusion stability, poor filament definition, and insufficient mechanical load-bearing capacity for orthopedic defects.
Engineering Approach
A tri-component ink combining Alginate, nano-Hydroxyapatite (nano-HAp), and Pluronic F-127 carrier, extruded through a 22G nozzle under 65–90 kPa. Extrusion and printability characterized via MG-63 cell trials.
Drug Delivery Nanoconjugate Programs
Nanoparticle-based encapsulation models engineered for sustained localized payload delivery.
CQD-Chrysin Drug Delivery
Nomenclature: Loading Efficiency and Sustained Release of CQD-Chrysin Nanoconjugates
GO-Chrysin Drug Delivery
Nomenclature: Loading Efficiency and Sustained Release of Graphene Oxide-Chrysin Nanoconjugates
Implantable Scaffolds & Diagnostic Studies
Narrative journals tracing our breakthroughs in patient-centric tissue fabrication and non-invasive diagnostics.
Bioresorbable Maxillofacial Implants: Moving Beyond Permanent Rigid Metal
Every year, millions of people around the world face broken bones, damaged joints, or worn-out skeletal regions that require surgical repair. For a long time, doctors have turned to metal implants to fix these problems. While they have helped countless patients walk, run, and live normally again, they are far from perfect.
Metal implants are inherently stiff and rigid compared to organic bone, causing continuous internal discomfort, localized bone degeneration, or complications years down the line. They are also expensive to manufacture, especially when each patient's anatomy is unique and demands an exact fit. Worse, many patients—particularly growing children—must endure traumatic secondary surgeries simply to remove or adjust the metal hardware as they heal.
Celutron's breakthrough bypasses this cycle by printing custom maxillofacial implants directly from patient CT scan DICOM data. Utilizing a smart, plant-based polymer matrix (PLA-HAp), the implant acts as a temporary framework that seamlessly fuses with real bone, guiding natural cellular growth, and then completely vanishes from the human body via bioresorption once its structural job is done.
Instead of forcing the patient to adapt to a rigid metal piece, these implants support natural healing, feel comfortable, and break down safely over time as real bone regrows in its place.
Breast Cancer Screening: Shattering the Cost Barrier for Health Equity
Early-stage detection of breast cancer changes lives, yet millions of women lack access to screening. Legacy diagnostic procedures—such as mammography or MRI imaging—remain concentrated in urban centers and carry massive financial barriers, costing up to ₹25,000 per session. For low-income and rural communities, this cost effectively makes early screening a luxury.
We developed a lightweight, wearable diagnostic patch sensor that completely bypasses the need for high-voltage machinery, external radiation, or expensive facilities. Powered purely by harvesting the patient's own body heat via advanced micro-thermoelectric generators, the patch maps cellular electrical permittivity changes and streams real-time wireless data to a clinician's dashboard.
By using simple, scalable organic materials, we have shattered the diagnostic price barrier down to a sub-₹500 threshold. This turns early cancer screening from a costly institutional hurdle into an accessible, safe, and routine checkup that can be conducted anywhere.
Shattering the diagnostic pricing model down to less than ₹500 is not just a technological optimization; it is a fundamental redirection of healthcare accessibility.
Oncology Cytogenetic Mapping: Unmasking the Drivers of the Tumor Battlefield
Cancer therapies are often a blind struggle. Clinicians administer highly toxic drugs like Paclitaxel or high-dose radiation therapies, waiting weeks for radiological scans to check if the tumor is shrinking or spreading. During this delay, aggressive tumors can mutate and bypass treatments entirely.
Our research team conducted a cytogenetic investigation to map the genetic locks that regulate aggressive tumor behavior. We succeeded in identifying and mapping a shared chromosomal breakpoint lock at Locus 6q23, which unmasks the dual oncological drivers: MYB (a primary breast adenoid cystic carcinoma driver) and BCLAF1 (its fusion partner).
By mapping this exact coordinate, alongside the neighboring GRM1 target at 6q24, we provide oncologists with a precision genetic blueprint. This makes it possible to track real-time chromosomal stability and tumor response during active, aggressive therapies, allowing for immediate treatment modifications.
We have unmasked the precise chromosomal target loci, mapping the coordinate drivers MYB + BCLAF1 and GRM1 to give clinicians a clear genetic blueprint of the battlefield.
R&D Milestones & Community Impact
A unified roadmap tracking our corporate laboratory engineering accomplishments alongside community health and training initiatives.
Company Founded
Celutron Innovations established in Chennai, incubated at Crescent Innovation and Incubation Council (CIIC).
DST Grant Awarded
Department of Science & Technology research grant through VIT-TBI.
Bioprinter RX-1 Prototype
First reconfigurable bioprinter prototype with modular printhead system.
Biomembrane B-10 Development
Multi-layered keratinocyte/fibroblast biomembrane fabrication protocol established.
Where Curiosity Turned Into Creation
3D Bioprinting Industrial Hands-On Workshop
What happens when science, technology, and hands-on curiosity come together in one room? That question came to life at our recently concluded workshop. Students, researchers, healthcare professionals, and biotech enthusiasts stepped into a fully hands-on experience with industrial-grade bioprinting equipment, preparing bioinks and turning digital designs into real, physical scaffolds. Guided by our team of experts, participants learned processes, prepared materials, and gained new perspectives on how their work could contribute to real-world tissue repair.
Pre-clinical Validations
Initial biocompatibility and cell viability testing under GLP conditions.
Turning Awareness Into Action
HPV Vaccination Awareness Drive
Every meaningful change starts with a conversation. This initiative brought together healthcare professionals, families, and young adults to break down vaccine myths, reduce hesitations, and build a safe space for proactive healthcare choices. Guided by medical voices, participants learned about early vaccination benefits and took active steps to protect long-term family health.
Bone Scaffold BS-4
Hydroxyapatite scaffold development with controlled porosity (50-90%).
Next-Gen Bioprinting Platform
Development of our next-generation advanced bioprinter featuring high-precision multi-material extrusion systems.
Metric Integrity Dashboard
Independent laboratory test results and validation assays verifying scaffold performance parameters.
| Validated Parameter | System Metric Value | Assay Validation Method | Clinical Status |
|---|---|---|---|
| Post-print cell viability | >85% | SEM + MTT assay | VALIDATED |
| Bone scaffold porosity | 72.3% | Mechanical characterization | VALIDATED |
| Scaffold interconnectivity | >95% | Micro-CT Scan | VALIDATED |
| Compressive strength improvement | 28× | Instron Mechanical Testing | VALIDATED |
| Drug loading efficiency (max) | 64.3% | NTA characterization | VALIDATED |
| Sustained release window | 36 hours | In-vitro UV-Vis Spectrometry | VALIDATED |
| CNF particle size (DES) | 155.8 nm | Nanoparticle Tracking Analysis (NTA) | VALIDATED |
Working on something similar?
We welcome collaborative opportunities, joint university publications, clinical trial partnerships, and institutional research inquiries.